LTGO · Latigo Biotherapeutics, Inc. · Investor Relations

Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive

THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the pricing of its upsized initial public offering of 19,200,000 shares of

Results demonstrated statistically significant pain reduction, rapid onset of analgesia, and opioid-sparing potential of investigational selective Nav1.8 inhibitor LTG-001 Marks only the second original research publication in the New England Journal of Medicine reporting clinical results for a

Veteran biopharmaceutical executive brings extensive commercial and product launch expertise THOUSAND OAKS, Calif. — July 8, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced the

Experienced chief financial officer brings deep financial and strategic leadership to Latigo’s board of directors Appointment supports continued operational growth THOUSAND OAKS, Calif. — April 8, 2026 — Latigo Biotherapeutics, Inc. (Latigo), a clinical-stage biopharmaceutical company committed to

Veteran biotech leader with more than 15 years of experience joins as Latigo advances non-opioid pain pipeline Appointment comes as Latigo builds toward late-stage development and broader corporate milestones THOUSAND OAKS, Calif. — March 3, 2026 — Latigo Biotherapeutics, Inc.

Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board Proceeds support advancement of company’s Na v 1.8 inhibitor clinical programs and development of broader pipeline THOUSAND OAKS, Calif. – March 17, 2025 – Latigo Biotherapeutics

LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial Fast Track designation will facilitate development and expedited regulatory review of LTG-001 THOUSAND OAKS, Calif., March 3, 2025 – Latigo Biotherapeutics (“Latigo”) today announced

Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience Walbert led recent acquisition of Horizon Therapeutics by Amgen for $28.3 billion THOUSAND OAKS, Calif., November 19, 2024 – Latigo Biotherapeutics (“Latigo”), a clinical-stage biotechnology

Potential best-in-class non-opioid Na v 1.8 inhibitor, LTG-305 aims to provide safer treatment for chronic pain by targeting underlying mechanisms of pain at its source Trial will evaluate safety, tolerability, and pharmacokinetics of LTG-305 in healthy volunteers through single- and